Company intelligence / Profile preview

Akrivista

Irvine*, California, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 3

Overview

No published clinical results as of the latest available information. The company focuses on developing novel therapies in ophthalmology, led by an experienced industry executive.

Therapeutic areas: ImmunologyOphthalmology
Modalities: Not explicitly stated; likely small molecules or biologics given focus on ophthalmology drug development[4][7]
Industry: Biotech

Drug pipeline

2 assets

NSR-REP1

Phase 3

Indications: Choroideremia

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships are publicly disclosed.

Beyond the preview

Go deeper on Akrivista.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akrivista.

Explore the full profile